DMG, or diffuse midline glioma, is an aggressive brain tumor that grows in the central structures of the brain and spinal cord. It primarily affects children, with 200 to 400 new diagnoses each year in the United States, making up roughly 10 to 15% of all childhood brain tumors. The median survival after diagnosis is about 13.7 months, though newer treatments are beginning to extend that timeline for some patients.
Where DMG Grows
Diffuse midline gliomas form in the midline structures of the central nervous system. The most common locations are the pons (a section of the brainstem that controls breathing, swallowing, and eye movement), the thalamus (a relay hub deep in the brain), the spinal cord, and the cerebellum. Because these tumors grow diffusely, meaning they spread through normal brain tissue like threads rather than forming a solid mass, surgical removal is almost never possible.
The Connection Between DIPG and DMG
If you’ve heard of DIPG, or diffuse intrinsic pontine glioma, you’re already familiar with the most well-known form of this disease. DIPG refers specifically to tumors in the pons, and for decades it was classified as its own diagnosis. In 2016, and again in the updated 2021 World Health Organization classification, scientists recognized that these pontine tumors share a critical molecular feature with similar tumors in the thalamus, spinal cord, and other midline locations. About 80% of DIPG cases carry the same defining genetic change.
The broader category is now formally called “Diffuse Midline Glioma, H3 K27-Altered.” DIPG is essentially a subset of DMG, one that happens to grow in the brainstem. The name change reflects the understanding that what makes these tumors deadly isn’t just where they grow, but the specific molecular error driving them.
What Causes DMG at the Molecular Level
The defining feature of most DMGs is a mutation in a histone protein, one of the structural proteins that DNA wraps around inside every cell. Normally, chemical tags on these proteins act like switches, telling genes when to turn on or off. In DMG, a mutation at a specific spot on the histone (the 27th position on the H3 protein) jams one of these switches permanently.
This mutation disables a molecular complex responsible for silencing certain genes. With that silencing system broken, genes that should stay quiet, including ones that promote uncontrolled cell growth, get turned on. At the same time, the mutation traps brain cells called oligodendrocyte precursor cells in an immature state, preventing them from developing normally. These stuck, rapidly dividing immature cells become the foundation of the tumor. Additional mutations then pile on, accelerating tumor growth.
Not every DMG carries the classic histone mutation. Some tumors achieve the same downstream effect through other molecular routes, which is why the WHO broadened the name from “H3 K27-mutant” to “H3 K27-altered” in 2021.
Symptoms to Recognize
Symptoms depend heavily on where the tumor forms, but they typically develop over weeks and worsen progressively. For tumors in the brainstem, the most common signs include facial drooping or weakness on one side of the face, difficulty swallowing or speaking, double or blurry vision, and problems with balance and walking. Children may appear increasingly clumsy.
Tumors in the thalamus or other locations can cause weakness or tingling in the arms and legs, seizures, difficulty concentrating, hearing changes, and problems with bladder or bowel control. Because these symptoms can initially look like other, less serious conditions, diagnosis sometimes takes weeks. An MRI typically reveals the characteristic appearance of a diffuse tumor in a midline structure, and in many brainstem cases, the imaging alone is enough for a preliminary diagnosis without a biopsy.
How DMG Is Treated
Radiation therapy has been the cornerstone of treatment for decades and remains the standard first-line approach. The typical course delivers radiation over about six weeks. A shorter course spread over roughly two and a half weeks has shown comparable results in clinical trials involving over 250 children, and some treatment centers now offer this condensed schedule to reduce the burden on families.
Radiation temporarily shrinks the tumor and often improves symptoms, sometimes dramatically. Children may regain the ability to walk or swallow more easily. But these improvements are temporary in the vast majority of cases, typically lasting several months before the tumor begins growing again.
Chemotherapy has historically shown little benefit for DMG. Dozens of clinical trials over several decades have failed to find a drug combination that meaningfully extends survival when added to radiation, which is one reason this disease has been so frustrating for families and researchers alike.
A New Treatment Showing Promise
In 2024, the FDA approved the first drug specifically for DMG. The medication, known as ONC201, works by disrupting the metabolic and molecular pathways that the H3 K27M mutation relies on. In clinical trials, patients who received ONC201 after their initial radiation but before the tumor recurred had a median survival of 21.7 months from diagnosis, compared to about 12 months in historical comparison groups. That difference was statistically significant.
About one-third of patients in the trials showed measurable tumor shrinkage, with responses typically appearing around seven to eight months into treatment. For patients whose tumors had already recurred before starting the drug, the benefit was more modest, with a median survival of 9.3 months from recurrence compared to 8.1 months historically. The drug is taken by mouth, which makes it more practical than intravenous treatments, particularly for children.
While these numbers represent a meaningful step forward, the survival rate at two years remains around 35%, and the disease is still considered incurable. Clinical trials are actively testing combinations of ONC201 with other therapies, immunotherapy approaches, and treatments targeting the specific molecular subtypes of DMG.
Prognosis and What Families Face
DMG carries one of the most difficult prognoses in pediatric oncology. The overall survival rate at 12 months is roughly 57%, dropping to about 35% at 24 months. Most children experience a period of improvement after radiation, followed by gradual decline as the tumor progresses. The timeline varies, with some patients surviving well beyond two years and a small number living longer, particularly with newer treatments.
The location of the tumor matters for prognosis. Thalamic DMGs have historically had slightly longer survival times than brainstem tumors, though both remain aggressive. Because the tumor grows in areas controlling fundamental functions like movement, breathing, and swallowing, the progression of the disease brings increasing neurological challenges that require significant supportive care.